Strides Pharma Science

Strides Pharma Science Working Capital Turnover

The Working Capital Turnover of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 9.00. In the previous year, Working Capital Turnover was 43.35 — a change of -79.24% (lower).

Working Capital Turnover

9.00

YoY

-79.24%

Last updated:

Working Capital Turnover of Strides Pharma Science is 2025 9.00 . Working Capital Turnover of Strides Pharma Science was 2024 43.35 . It decreases by -79.24% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Working Capital Turnover of Strides Pharma Science is 9.00 in 2025.

Working Capital Turnover of Strides Pharma Science changed from 43.35 to 9.00, representing a -79.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Strides Pharma Science

All Key Metrics — Strides Pharma Science